This report covers the 7 major markets and provides an Excel-based forecast model for the Multiple Sclerosis (MS) market through 2034.
The analyst estimated that the PD market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%.
The major drivers of growth in the PD market will be the launch of new disease modifying therapies (DMTs) with new mechanisms of action (MOAs) across the 7MM that target MS disease progression which will also increase treatment rates during the forecast period, and a trend towards the use of high-efficacy treatments such as anti-CD20 monoclonal antibodies (mAbs), which have high annual costs of therapy and high patient compliance rates.
Brand erosion due to the emergence of biosimilars and generic small molecules will hamper the future growth of the global MS market.
The analyst estimated that the PD market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%.
The major drivers of growth in the PD market will be the launch of new disease modifying therapies (DMTs) with new mechanisms of action (MOAs) across the 7MM that target MS disease progression which will also increase treatment rates during the forecast period, and a trend towards the use of high-efficacy treatments such as anti-CD20 monoclonal antibodies (mAbs), which have high annual costs of therapy and high patient compliance rates.
Brand erosion due to the emergence of biosimilars and generic small molecules will hamper the future growth of the global MS market.
Scope
- Overview of Multiple Sclerosis, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Multiple Sclerosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Multiple Sclerosis therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Multiple Sclerosis treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global Multiple Sclerosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Multiple Sclerosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Multiple Sclerosis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Analyst
1 Multiple Sclerosis: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Co
- Novartis AG
- Merck KGaA
- Biogen Inc
- Mitsubishi Tanabe Pharma Corp
- MediciNova Inc
- Pfizer Inc
- Banner Life Sciences LLC
- AB Science SA
- Immunic Inc
- Sanofi
- MediciNova (Europe) Ltd
- TG Therapeutics Inc
- Clene Nanomedicine Inc
- InnoCare Pharma Ltd
- Handa Pharmaceuticals Inc